Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EVOLOCUMAB Cause Injection site swelling? 1,933 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 1,933 reports of Injection site swelling have been filed in association with EVOLOCUMAB (REPATHA). This represents 1.3% of all adverse event reports for EVOLOCUMAB.

1,933
Reports of Injection site swelling with EVOLOCUMAB
1.3%
of all EVOLOCUMAB reports
1
Deaths
32
Hospitalizations

How Dangerous Is Injection site swelling From EVOLOCUMAB?

Of the 1,933 reports, 1 (0.1%) resulted in death, 32 (1.7%) required hospitalization, and 4 (0.2%) were considered life-threatening.

Is Injection site swelling Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 1,933 reports have been filed with the FAERS database.

What Other Side Effects Does EVOLOCUMAB Cause?

Device difficult to use (31,807) Drug dose omission by device (23,957) Wrong technique in product usage process (21,664) Accidental exposure to product (16,160) Injection site pain (9,988) Product storage error (6,606) Back pain (5,254) Myalgia (5,061) Drug dose omission (4,914) Injection site bruising (4,409)

What Other Drugs Cause Injection site swelling?

ETANERCEPT (9,992) DUPILUMAB (9,582) ADALIMUMAB (4,428) GLATIRAMER (1,836) IXEKIZUMAB (1,615) TIRZEPATIDE (1,131) ENBREL (1,121) HYDROXYPROGESTERONE CAPROATE (924) HUMIRA (838) CERTOLIZUMAB PEGOL (782)

Which EVOLOCUMAB Alternatives Have Lower Injection site swelling Risk?

EVOLOCUMAB vs EXELON EVOLOCUMAB vs EXEMESTANE EVOLOCUMAB vs EXENATIDE EVOLOCUMAB vs EXFORGE EVOLOCUMAB vs EXJADE

Related Pages

EVOLOCUMAB Full Profile All Injection site swelling Reports All Drugs Causing Injection site swelling EVOLOCUMAB Demographics